CEO Jarle Bruun will be presenting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic 2025 conference.The abstract entails an integrated pharmacological analysis of patient-derived colorectal cancer tumoroids established in the TargetCRC study. Strong predictive associations to approved and emerging drugs as well as novel combinations are revealed.
The work comes out of a collaboration with Akershus University Hospital and Institute for Molecular Medicine (Finland).